Asia Deal Watch: Rhizen Licenses Chinese Rights For PI3K Inhibitor To Curon

 
• By Ian Haydock, Vibha Ravi, Jung Won Shin, Joseph Haas, Brian Yang, and Anju Ghangurde

Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.

Asia Deal Watch

More from Deals

More from Business